Onco Actu du 27 juin 2017

	2. Etiologie
Night shift work may stop body repairing daily damage to DNA and trigger cancer, study suggests [The Telegraph] The study tested 50 night shift workers for levels of 8-OH-dG - a chemical which is produced when DNA is repaired. They then tested them again when they were working days, and found levels jumped by 300 per cent.
	2.6 Etiologie - Environnement
California to list glyphosate as cancer-causing; Monsanto vows fight [Reuters] Monsanto vowed to continue its legal fight against the designation, required under a state law known as Proposition 65, and called the decision "unwarranted on the basis of science and the law."
	3.1.1 Tabac - e-cigs
Vaping teens more likely to take up regular cigarettes [Reuters] Soneji and colleagues analyzed data from nine smaller studies with a total of 17,389 participants ages 14 to 30.
	4. Dépistage, diagnostic et pronostic
The Lab Says It’s Cancer. But Sometimes the Lab Is Wrong. [NY Times] But what about mix-ups that are not so obvious — two lung tissue samples that are switched, or two breast samples? Dr. Pfeifer turned to DNA fingerprinting to determine how often such samples are mixed up at Washington University.
	4.1 Dép., diag. & prono. - Prostate
The New Health Care: The ABCs and Ds of Whether to Get Prostate Cancer Screening [NY Times] Although there seemed to be a lot of coverage of this announcement in the news media, and a fair amount of excitement, there are two things men should know. First, it’s a good thing that recommendations change over time; second, this change isn’t as big a deal as you might think.
	4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
Fast, precise cancer care is coming to a hospital near you [Wired] Getting the FDA to approve that amalgam of tests wasn’t easy.
	4.2 Dép., diag. & prono. - Génome
Whole genome sequencing not ready for routine use: study [Reuters] Heidi Rehm, director of the Laboratory for Molecular Medicine at the Brigham, said the researchers were surprised at how many healthy people carried risk variants for rare genetic diseases. That suggests that risk of rare disease could be "far higher than previously suspected," she said in a statement.
You can get your whole genome sequenced. But should you? [Wired] The study is also too small too to suggest that all primary care doctors are ready to be put on the front lines of genetic medicine.
Routine DNA Sequencing May Be Helpful And Not As Scary As Feared [NPR] Half of the volunteers had their DNA scanned for genetic variations that could cause nearly 5,000 rare genetic diseases as well as other genetic markers. The other half answered questions about diseases that ran in their families — the traditional way of spotting inherited risks.
In healthy patients, genome sequencing raises alarms while offering few benefits [STAT] The researchers said that none of the 11 patients benefitted from their “molecular diagnosis,” at least in the short term. That included the two who did have the disease their mutation is expected to cause but had not previously been diagnosed.
DNA Testing Reveals the Chance of Bad News in Your Genes [MIT Technology Review] Out of 50 healthy adults who had their genomes sequenced, 11—or 22 percent—discovered they had genetic variants in one of nearly 5,000 genes associated with rare inherited diseases. One surprise is that most of them had no symptoms at all.
One in five 'healthy' adults may carry disease-related genetic mutations [Science] “We like a quick fix and the gene is an important cultural icon right now, so we probably give it more power than it really has,” Koenig says. “But these are still really early days for these technologies to be useful in the clinic.”
	5.10 Traitements - Essais
New bladder cancer therapy to start clinical trials [Cancer Research UK] The new treatment called STK-01 is being developed to improve delivery of chemotherapy for non-muscle invasive bladder cancer (NMIBC), in patients whose tumour has not yet penetrated into the muscle layer of the bladder wall.
	5.12 Immunothérapies
Using ‘sticky’ nanoparticles, researchers develop new strategy to boost body’s cancer defenses [UNC] “If fully clinically translated, this will change cancer immunotherapy,” Wang said. “This technology has the potential to improve the efficiency of cancer immunotherapy checkpoint inhibitors, which would mean longer survival for multiple cancer types.”
	5.2 Pharma
Can Adcetris' narrow beat in new trial win a new FDA nod? Seattle Genetics, Takeda hope so [FiercePharma] Still, that 5% difference could be a tough sell with increasingly cost-conscious payers, and investors know it. Seattle Genetics’ shares dropped 11% as the data were released.
Seattle Genetics Drug Scratches Out Win In Hodgkin Lymphoma [Forbes] Siegall says that Adcetris will cost about $100,000 to $120,000 for the average first-line Hodgkin patient, depending on the patient's weight and the exact number of doses given.
Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma [Seattle Genetics] The two-year modified PFS rate for patients in the ADCETRIS arm was 82.1 percent compared to 77.2 percent in the control arm.
Seattle Genetics, Takeda lymphoma drug succeeds late-stage trial [Reuters] "Eliminating bleomycin should be enough to ensure commercial success with a broad label," Morgan Stanley analysts said.
	5.3 Traitements - FDA, EMA, NICE...
EMA Offers New EudraVigilance Checklist for Sponsors, MAHs [RAPS] The European Medicines Agency (EMA) on Monday published a checklist to help marketing authorization holders (MAHs) and sponsors prepare for the technical changes ahead of the launch of the new EudraVigilance adverse event system on 22 November 2017.
	5.4 Traitements - Economie
EU tests limits of drug pricing freedom in landmark probe [Reuters] "Normally, in Europe, drug companies just have to negotiate with a national regulator on pricing. Now there is the prospect of additional European-level oversight and that is scary for the industry."
	5.9.3 EHA
ImmunoGen Presents Data from Phase I Study of IMGN779 in Acute Myeloid Leukemia [ImmunoGen] Dose-dependent biological and anti-leukemia activity observed.
	6. Lutte contre les cancers
Precision Medicine: the Promise vs. the Reality [University of Michigan] Scientists find great potential in using genetic sequencing to help direct targeted cancer therapy, but practicing oncologists see some important limitations.
Speaking The Same Language: The ESMO Glossary In Personalised Medicine [ESMO] Fabrice André tells us why he thinks the soon-to-be-released ESMO Glossary in Personalised Medicine—a list of definitions in precision medicine and biomarkers—is an important tool for improving understanding and communication in this field and should be essential reading for every oncologist.
Hunted, haunted, stateless and scared: the stories of refugee scientists [Nature] Displaced researchers face huge challenges making lives abroad, even if they find work.
	6.10 Politiques
Experts warn of chaotic fallout from post-Brexit nuclear plan [The Times] Britain’s Brexit plan will plunge its nuclear power plants, cancer treatment centres and leading research facilities into chaos within two years, according to a secret government assessment.
	6.11 Patients
Developing a Survivorship Taxonomy That Puts People First [ASCO Connection] The term survivorship care was created to define the scope of this work, and, somewhere along the way, the name was given to the recipients of that care. We know that not everyone likes it.
	6.3 Associations/Fondations
Launching the Biden Cancer Initiative [BDI] The Biden Cancer Initiative will develop and drive implementation of solutions to accelerate progress in cancer prevention, detection, diagnosis, research and care, and to reduce disparities in cancer outcomes.
AACR Applauds Launch of Biden Cancer Initiative [AACR] "The AACR looks forward to working with Mr. and Dr. Biden and their team on numerous initiatives that will result in an acceleration of advances in cancer research for the benefit of improvements in patient care.”
	6.4 Médico-éco
Medicaid cuts linked to later breast cancer diagnosis [Reuters] In low-income areas, where more residents were insured through Medicaid, the proportion of breast cancer cases diagnosed at a late stage when tumors had spread rose from 35.4 percent in 2002-2004 – before the Medicaid cuts – to 40.2 percent in 2006-2008, researchers note in the journal Cancer.
	6.9 Controverses
The NIH is squandering an opportunity to fund more researchers [STAT] The NIH proposed the GSI for three reasons: to ensure the best oversight of taxpayers’ money, to increase the possibility of new scientific breakthroughs, and to help train the next generation of promising researchers. It now wants to replace this dramatic and concrete plan with a vague alternative that ignores their previous noble goals. That’s not the kind of progress that the NIH should dedicate itself to.